Showing results (31-40 of 3,874) with videos related to
Sort By:
Pageof 388
International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity|October 24, 2001
Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine releaseI C Kilpatrick, M Traut, D J HealNeuropharmacology|February 9, 2012
What is the prognosis for new centrally-acting anti-obesity drugs?David J Heal, Jane Gosden, Sharon L SmithInternational Journal of Obesity (2005)|March 14, 2012
A review of late-stage CNS drug candidates for the treatment of obesityD J Heal, J Gosden, S L SmithCurrent Topics in Behavioral Neurosciences|May 4, 2022
New Drugs to Treat ADHD: Opportunities and Challenges in Research and DevelopmentDavid J Heal, Jane Gosden, Sharon L SmithJournal of Psychopharmacology (Oxford, England)|July 28, 2016
The NK1R-/- mouse phenotype suggests that small body size, with a sex- and diet-dependent excess in body mass and fat, are physical biomarkers for a human endophenotype with vulnerability to attention deficit hyperactivity disorderKatharine Pillidge, David J Heal, S Clare StanfordProgress in Neuro-Psychopharmacology & Biological Psychiatry|July 1, 1994
Common profile of D1 receptor antagonists and atypical antipsychotic drugs revealed by analysis of dopamine turnoverD J Heal, C Czudek, W R BuckettNeuropharmacology|June 24, 2014
Dopamine reuptake transporter (DAT) "inverse agonism"--a novel hypothesis to explain the enigmatic pharmacology of cocaineDavid J Heal, Jane Gosden, Sharon L SmithNeuropharmacology|February 11, 2018
Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humansDavid J Heal, Jane Gosden, Sharon L SmithBritish Journal of Clinical Pharmacology|December 17, 2009
Regulatory challenges for new drugs to treat obesity and comorbid metabolic disordersDavid J Heal, Jane Gosden, Sharon L SmithPharmacology, Biochemistry, and Behavior|June 19, 1998
The anxiogenic agents, yohimbine and FG 7142, disrupt the noradrenergic response to noveltyK Mason, D J Heal, S C StanfordPageof 388